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Abstract
Background: Biofilms are associated with persistent infection. Reports characterizing clinical infectious outcomes
and patient risk factors for colonization or infection with biofilm forming isolates are scarce. Our institution recently
published a study examining the biofilm forming ability of 205 randomly selected clinical isolates. This present
study aims to identify potential risk factors associated with these isolates and assess clinical infectious outcomes.
Methods: 221 clinical isolates collected from 2005 to 2012 and previously characterized for biofilm formation were
studied. Clinical information from the associated patients, including demographics, comorbidities, antibiotic usage,
laboratory values, and clinical infectious outcomes, was determined retrospectively through chart review. Duplicate
isolates and non-clinical isolates were excluded from analysis. Associations with biofilm forming isolates were
determined by univariate analysis and multivariate analysis.
Results: 187 isolates in 144 patients were identified for analysis; 113 were biofilm producers and 74 were not
biofilm producers. Patients were primarily male (78 %) military members (61 %) with combat trauma (52 %). On
multivariate analysis, the presence of methicillin-resistant Staphylococcus aureus (p < 0.01, OR 5.09, 95 % CI 1.12,
23.1) and Pseudomonas aeruginosa (p = 0.02, OR 3.73, 95 % CI 1.46, 9.53) were the only characteristics more likely
to be present in the biofilm producing isolate group. Infectious outcomes of patients with non-biofilm forming
isolates, including cure, relapse/reinfection, and chronic infection, were similar to infectious outcomes of patients with
biofilm-forming isolates. Mortality with initial infection was higher in the biofilm producing isolate group (16 % vs 5 %,
p = 0.01) but attributable mortality was low (1 of 14). No characteristics examined in this study were found to be
associated with relapse/reinfection or chronic infection on multivariate analysis.
Conclusions: Bacteria species, but not clinical characteristics, were associated with biofilm formation on multivariate
analysis. Biofilm forming isolates and non-biofilm forming isolates had similar infectious outcomes in this study.
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Background
The ability of microorganisms to form biofilms, a sessile
mode of growth intrinsically associated with antimicro-
bial resistance and recalcitrant infection, is a current
topic of interest as it may constitute a virulence factor in
human infections [1]. This phenotype has been observed
in vivo through scanning electron microscopy in many
situations. This observation has led to the implication of
biofilms in a majority of human infections [2]. Biofilm
formation also has been linked with poor wound healing
[3], burn wound ulceration [4], and medical implanted
device related infections [5]. Treatment of infections
with biofilm forming bacteria is notoriously difficult, and
requires higher doses or combination of antibiotics, and
removal of foreign bodies when implicated in device re-
lated infections [1, 6].
Despite an increased understanding of this process
and the observation of the presence of biofilms in
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important infections, most studies have described this
phenomenon in vitro. There are few studies which estab-
lish a link between the biofilm-forming phenotype of
these organisms and clinical infectious outcomes or that
identify risk factors for expression of the phenotype.
Limitations with the study of biofilms in vitro include
the omission of host factors present at sites of infection
(e.g. plasma proteins), which can stimulate biofilm for-
mation [7], the lack of standardization among laboratory
methods for characterizing biofilm phenotypes in vitro,
and the lack of clinically available in vivo assays. Re-
cently, we examined the phenotypic and genotypic
characteristics of 205 randomly selected clinical bacter-
ial isolates with respect to their ability to form biofilms
[8], and we noticed biofilm formation was observed in
isolates serially recovered from presumed ongoing in-
fections in several patients. Clinical information associ-
ated with the isolates, however, was not collected, and
the significance of this observation was not known. To
better understand clinical risk factors for acquisition
of biofilm-forming organisms and then to examine
whether an isolate’s ability to form biofilms played a
role in the outcomes of infection, we retrospectively




Two hundred twenty one clinical isolates of the species
Acinetobacter calcoaceticus-baumannii complex, Escher-
ichia coli, Klebsiella pneumoniae, Pseudomonas aerugi-
nosa, and Staphylococcus aureus, collected from January
2005 to June 2012 were randomly selected from a bac-
terial repository at San Antonio Military Medical Center
(Fort Sam Houston, TX, USA), including the 205 previ-
ously described [8]. This strain repository includes all
isolates recovered from patients enrolled in prospective
studies at our institution, regardless of their antimicro-
bial susceptibility, as well as multidrug resistant isolates
recovered from the general patient population. The bio-
film forming ability of these isolates was previously char-
acterized in vitro using the semi-quantitative microtiter
plate biofilm formation assay, in which the absorbance of
solubilized crystal violet of each selected isolate is com-
pared to a known biofilm forming strain [9]. In this way,
biofilm formation was graded as positive or negative as
compared to a positive control.
Study subjects contributing to the previously reported
isolates [8], subject to additional exclusion criteria, were
selected for further study. Duplicate isolates, defined as
isolates of the same species and PFGE type, recovered
from the same anatomical site within 10 days of the
matching isolate and having concordant categorical
biofilm-forming phenotypes, were omitted. Thus, only
single-patient unique isolates were included in the study.
Non-clinical isolates, such as those related to surveil-
lance swabs obtained for infection control purposes,
were also excluded, along with isolates recovered from
patients <18 years old and those which could not be
linked to source patients.
Clinical data
For the study subjects with bacterial isolates meeting the
defined criteria and included in this study, the potential
clinical predictors of infection or colonization and asso-
ciated clinical outcomes of infection were extracted from
the medical record. These included basic demographics,
medical comorbidities (coronary artery disease, chronic
kidney disease, diabetes), circumstances of injury (mili-
tary service, deployment exposure, combat trauma),
presence of burn and percent total body surface area
burned (TBSA). Laboratory data including hematocrit,
white blood cell count, platelet count, erythrocyte sedi-
mentation rate (ESR), and c-reactive protein (CRP) on
the day of admission, day of isolate recovery, and day of
discharge were recorded. Microbiological data included
the identity of primary and co-infecting organisms, as
well as receipt of antibiotics prior to recovery of clinical
isolates. The anatomic source of isolates and their asso-
ciation with clinical support devices (such as implanted
orthopedic devices, intravascular catheters, urinary cath-
eters, etc.) was also obtained from the medical record,
using radiographs where appropriate.
Infecting organisms were distinguished from coloniz-
ing organisms by chart review based upon clinical cir-
cumstances, using established definitions (asymptomatic
bacteriuria [10], central line associated bloodstream in-
fection [11], catheter associated urinary tract infection
[12], ventilator associated pneumonia [13]), and reviewer
physician judgment. Outcomes including clinical cure,
relapse/reinfection and chronic infection were also re-
corded. Length of follow up was greater than 24 months.
Relapse or reinfection was defined as recovery of an or-
ganism from the same site more than 10 days after a
period of culture negativity, or clinical quiescence after
treatment with presumed cure. Chronic infection was de-
fined as the continued, intermittent recovery of organisms
while on antibiotics, or immediate return of infectious
symptoms after cessation of antibiotic therapy, with no
period of clinical quiescence while off of antibiotic ther-
apy. In-hospital death was recorded, and the documented
cause of death was cross- referenced to autopsy informa-
tion, where available.
All data were collected through chart review by a single
investigator to minimize variation in collection strategy.
Study design was approved by the San Antonio Military
Medical Center Institutional Review Board with a waiver
of informed consent.
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Statistical analysis
Data were examined for normal vs. non-parametric distri-
bution using the Kolmogorov-Smirnov test. For univariate
analysis, differences in frequencies were determined using
Pearson’s chi-square or Fisher’s exact tests, while the
Mann–Whitney-U test was used to examine differences in
the medians of continuous data. Standard multivariate
analysis was performed using multiple logistic regression,
including in the model predictive variables having univari-
ate p-values <0.2. Statistical calculations were performed
using SPSS (IBM SPSS v19.0) and p-values of <0.05 were
considered statistically significant.
Results
Patient demographics and characteristics
Of the 221 isolates, 34 isolates from 26 patients were ex-
cluded. Of these, 18 were non-clinical isolates, 13 iso-
lates from 5 patients were duplicates, two were obtained
from patients <18 years old, and one could not be un-
equivocally associated to a source patient. Therefore,
187 isolates associated with unique infectious events in
144 patients were included in the analysis. Both biofilm
producing and non-biofilm producing bacteria were re-
covered from 12 patients. Of those, 7 patients had com-
plex polymicrobial wounds with the isolates recovered
from the same site; the other events were unrelated. No
similarities were noted amongst the patients. Patients
were primarily male (78 %) military members (61 %)
with combat trauma (52 %). Demographic information
of the patients from whom biofilm producing bacteria
were recovered (n = 79) was not significantly different
from demographic information of the patients from
whom non-biofilm producing bacteria were recovered
(n = 53) (Table 1). Including these 12 patients in the
analysis did not reveal any significant differences in
demographic variables between the two groups (data
not shown).
Analysis of possible associations with biofilm formation
In univariate analysis, male gender, military service and
combat trauma were significantly more common in the
biofilm producing isolate group; whereas the only clinical
complication associated with the non-biofilm producing
group among this cohort was diabetes. Biofilm producing
isolates were more often associated with and isolated from
various anatomical sites, including respiratory cultures,
wound cultures, as well as orthopedic device related infec-
tions. In contrast, non-biofilm producing isolates were sig-
nificantly associated with urine cultures. Bacterial species
significantly observed to be associated with the biofilm
producing group were P. aeruginosa and methicillin-
resistant S. aureus (MRSA); whereas E. coli was more
commonly associated with the non-biofilm producing
group. Interestingly, no significant correlation for either
group was determined for isolates of A. calcoaceticus-
baumannii complex and K. pneumoniae (Table 2).
Laboratory data, medical comorbidities, and antibiotic
exposure prior to recovery of isolate were not different
between the two groups. In multivariate analysis, pres-
ence of MRSA (p < 0.01) (OR 5.09, 95 % CI 1.12, 23.1)
and P. aeruginosa (p = 0.02) (OR 3.73, 95 % CI 1.46, 9.53)
were the only characteristics found to be more likely to be
present in the biofilm producing isolate group with E.
coli less likely present in that group (p = 0.01), with an
odds ratio of 0.07 and 95 % CI (0.03, 0.2).
Clinical infectious outcomes of patients with respect to
biofilm formation
Infectious outcomes of patients with biofilm producing
isolates including infection, infection versus colonization,
cure of first infection, relapse/reinfection, and chronic in-
fection, were similar to those with non-biofilm producing
isolates. All-cause mortality during the initial infection
was significantly more common in patients carrying bio-
film producing isolates (16 % vs 5 %, p = 0.01) (Table 3).
Of the three patients who died during initial infection with
a non-biofilm forming isolate, one died due to sepsis and
multisystem organ failure caused by a study isolate; the
remaining two deaths were attributed to a fungal brain
abscess and one to a necrotic bowel, respectively. Two
of these patients had suffered burns, 2 were male, with
a median age 36, and a median TBSA burn of 55 %.
The isolates were A. calcoaceticus-baumannii complex
(n = 2), and P. aeruginosa (n = 1), and were recovered
blood (n = 2), or wound cultures (n = 1).
Of the 14 patients who died during the first infection
with a biofilm-forming isolate, only one was due to mul-
tisystem organ failure from sepsis attributable to a study
isolate. The remaining 13 deaths were due to ischemic
Table 1 Demographics of patients with biofilm producing







Number of Patients 79 53
Median Age, years (IQR) 30 (22, 44) 34 (24, 60) 0.64
Male 66 (84 %) 37 (70 %) 0.10
Military Service 53 (67 %) 28 (53 %) 0.13
Combat Trauma 44 (56 %) 24 (45 %) 0.30
Burn Patients 30 (38 %) 12 (23 %) 0.08
Median % TBSA burn (IQR) 52 % (36, 78) 55 % (48, 66) 0.31
Coronary Artery Disease 4 (5 %) 6 (11 %) 0.16
Chronic Kidney Disease 1 (1 %) 1 (2 %) 0.33
Diabetes mellitus 5 (6 %) 8 (15 %) 0.16
TBSA- total body surface area
aexcluding 12 patients represented in both groups
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bowel/abdominal compartment syndrome (n = 5), sepsis
unrelated to study isolate (n = 3), withdrawal of care
due to underlying non-infectious illness (n = 2), invasive
fungal infection (n = 1), ventilator associated pneumo-
nia/respiratory failure (n = 1), and multisystem organ
failure (n = 1). These patients also suffered burn injuries
(n = 10) with a median TBSA of 55 %, and were male
(n = 12), with a median age of 32. The isolates from
those patients included A. calcoaceticus-baumannii
complex (n = 3), K. pneumoniae (n = 3), P. aeruginosa
(n = 7), and MRSA (n = 1). Ten of these study isolates
were recovered from wounds, 2 from blood culture, and 1
from a sputum culture.
Analysis of characteristics associated with relapse/reinfection
or chronic infection
Characteristics associated with relapse/reinfection or
chronic infection identified on univariate analysis included
higher percentage TBSA (77 % versus 53.5 %, p <0.01),
infection with P. aeruginosa (23 % vs 9 %, p = 0.03) or
infection with methicillin-sensitive S. aureus (MSSA) (17 % vs
1 %, p < 0.01). Recovery of an isolate from a wound culture
Table 2 Clinical and microbiologic characteristics associated with isolates of the biofilm producing and non-biofilm producing groups
Biofilm producing isolates Non-biofilm producing isolates Univariate P-Value Multivariate P-Value
Number of Isolates 113 74
Male 101 (89 %) 56 (76 %) 0.01 NS
Military 86 (76 %) 41 (55 %) <0.01 NS
Combat Trauma 74 (65 %) 35 (47 %) 0.01 NS
Burn 54 (48 %) 27 (36 %) 0.13 NS
Median % TBSA burn (IQR) 60 % (37, 79) 55 % (48, 63) 0.36
Coronary Artery Disease 4 (4 %) 7 (9 %) 0.09 NS
Chronic Kidney Disease 1 (1 %) 1 (1 %) 0.76
ESRD 0 (0 %) 2 (3 %) 0.08 NS
Diabetes 6 (5 %) 11 (15 %) 0.03 NS
Median Hct on Culture Date g/dl (IQR) 24.2 (22, 30) 24.1 (22, 31) 0.67
Median WBC on Culture Date 103 cells/μl (IQR) 9.6 (6, 13) 9 (6, 12) 0.62
Median ESR on Culture Date mm/hr (IQR) 95 (57, 114) 79 (67, 106) 0.77
Median CRP on Culture Date mg/dl (IQR) 16.6 (8, 24) 12.25 (5, 20) 0.21
Received Appropriate Empiric Antibiotics 47 (42 %) 32 (43 %) 0.74
Median Prior Duration of Antibiotics, Days (IQR) 4 (2, 8) 4 (2, 8) 0.52
A. calcoaceticus-baumannii complex (n = 53) 29 (55 %) 24 (45 %) 0.32
E. coli (n = 34) 5 (14 %) 29 (85 %) <0.001 0.01
K. pneumoniae (n = 44) 32 (71 %) 12 (27 %) 0.06 NS
P. aeruginosa (n = 34) 28 (82 %) 6 (18 %) <0.01 <0.01
S. aureus (n = 22) 19 (86 %) 3 (14 %) 0.01 NS
MSSA (n = 6) 5 (83 %) 1 (17 %) 0.24
MRSA (n =16) 14 (87.5 %) 2 (12.5 %) 0.02 0.02
Polymicrobial Eventa 39 (35 %) 20 (27 %) 0.28
Blood Culture 20 (18 %) 21 (28 %) 0.08 NS
Central Line Associated 2 (10 %, n = 20) 4 (19 %, n = 21) 0.09 NS
Respiratory Culture 10 (9 %) 1 (1 %) 0.03 NS
Urine Culture 3 (3 %) 18 (24 %) <0.01 NS
Foley Catheter Associated 1 (33 %, n = 3) 4 (22 %, n = 18) 0.50
Wound Culture 80 (71 %) 34 (46 %) <0.01 NS
Orthopedic Device Related 15 (19 %, n = 80) 4 (12 %, n = 34) <0.01 NS
Median Number of Surgeries (IQR) 5.5 (2, 9) 6 (2, 10) 0.56
TBSA total body surface area, Hct hematocrit, WBC white blood cell count, ESR erythrocyte sedimentation rate, CRP c-reactive protein, MSSA methicillin susceptible
S. aureus, MRSA methicillin-resistant S. aureus
aisolate recovered from a site with more than one organism recovered
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was more common in patients who were cured (68 % vs
37 %, p <0.01). Laboratory data, medical comorbidities,
antibiotic exposure prior to recovery, and association with
medical devices was implicated on univariate analysis with
relapse/reinfection or chronic infection. In multivariate
analysis, no factors were significantly associated with re-
lapse/reinfection or chronic infection (Table 4).
Discussion
Notably, no clinical variables were found to be independ-
ently associated with biofilm formation in our study. Un-
like previous studies, we did not observe biofilm formation
to be statistically associated with relapse/reinfection, or
chronic infections [14]. These prior studies examine mainly
chronic diabetic or vascular stasis ulcers, which were not
the type of wounds in our population; many of our patients
underwent aggressive serial debridement of wounds, which
is a unique aspect of trauma care. This result also differs
from our earlier publication on these isolates, in which bio-
film formation was observed in isolates serially recovered
from ongoing infections in several patients [8]. With the
present study, clinical information recovered from
chart review was able to differentiate colonizing from
infecting organisms, distinguish between discrete infec-
tions, and assess for outcome. A case control study re-
cently published from our institution, with a different
patient population and bacterial isolates, demonstrated
that biofilm formation was associated with persistence of
skin and soft tissue wound infection beyond 14 days [3].
Although no differences were found between biofilm pro-
ducing isolates versus non-producing isolates and cure,
correlation to wound persistence or duration of infection
was not examined in this study.
Interestingly, we did not find significant differences
in previous antibiotic exposure or duration of antibiotic
exposure prior to organism recovery among biofilm
formers either on univariate or multivariate analysis.
Some authors have found that antibiotic exposure can
induce biofilm formation in vitro [15]. It is possible that
this phenomenon is not replicated in vivo, or that the
analysis is confounded by the relatively high rate of previ-
ous antibiotic exposure in this population in whom severe
trauma is common.
More deaths occurred with initial infections by biofilm-
producing isolates overall, but the attributable mortality
(i.e. death from infection) remained low (1 out of 14). The
reasons for this are not immediately clear as both groups
were similar with respect to presence of burn, TBSA of
burn, gender, age, and site of recovery; although low num-
bers in the comparator group make drawing conclusions
difficult. Our literature search did not reveal any studies
addressing this issue.
In univariate analysis, higher percentage TBSA was
found to be associated with relapse/reinfection, or chronic
infection. This is similar to findings indicating that the risk
of burn wound infection increases in proportion to the
amount of body surface area burned [16]. MSSA was
more likely to be associated with relapse/reinfection, and
chronic infection, but this analysis is limited by the small
sample size (6 isolates). Study isolates recovered from
wound infections were more likely to be cured without
relapse or reinfection; perhaps this reflects the ability
to obtain a surgical cure through tissue debridement.
However, no clinical variables or microbiological charac-
teristics were found in this study in multivariate analysis
to be independent predictors of relapse/reinfection or
chronic infection.
There are several limitations notable in this study. As a
retrospective study, our data are subject to selection bias
and misclassification bias, particularly since we were
not able to control for these potential influences.
Utilization of a randomly selected sample had conse-
quences in microorganism representation as well as
demographics. Species were unevenly represented in
this sample (6 MSSA versus 53 A. calcoaceticus-baumannii
complex). However, this distribution was similar to
prospectively-acquired data from military casualties having
persistent wound infections [3]. A majority of the isolates
selected were biofilm producers. This may be due to the
selection of isolates from a repository containing many
multidrug resistant isolates. This composition may not ac-
curately represent the frequency of biofilm formation
among isolates in an unselected population, but did allow
for the study of large numbers of biofilm and non-biofilm
forming isolates.
Common medical comorbidities, such as coronary ar-
tery disease (10 of 144 patients) and diabetes (13 of 144
patients) were also underrepresented; this may have
been the result of sampling bias from our burn center,
the young age of patients in the cohort, or inaccurate
documentation of patients’ past medical history. There
are likely too few cases to reasonably draw conclusions
regarding the presence of biofilm forming isolates and
these medical comorbidities.
Table 3 Correlation of clinical outcomes of infections to biofilm







Total Infecting Isolates 88 (78 %, n = 113) 60 (81 %, n =74) 0.60
Death during Initial
Infection
14 (16 %, n = 88) 3 (5 %, n = 60) 0.01
Cure Without
Relapse/Reinfectiona
55 (74 %, n = 74) 46 (81 %, n = 57) 0.39
Relapse/Reinfectiona 18 (24 %, n = 74) 11 (19 %, n =57) 0.49
Chronic Infectiona 1 (1 %, n = 74) 0 1
aexcluding patients who died during initial infection
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With regards to medical device-related infections,
despite a large overall isolate database, we observed
only 19 orthopedic device related infections, 5 urinary
catheter related infections, and 6 central line related infec-
tions. The small numbers in these cohorts could explain
why no association was found with catheter associated
infections and also explain why the association with
orthopaedic devices was not significant on multivariate
analysis. Future studies could include a sample size de-
termined by power analysis to detect differences for all
potential associations.
Unlike previous studies [17], recovery of organism
from a polymicrobial culture site was not correlated with
biofilm producing isolates. Data examining the biofilm
producing capability of the co-located organisms were
not available due to the retrospective nature of this
study; it is possible that a non-study isolate was a biofilm
producer and co-located with the study isolate. With
these in mind, future studies should investigate the char-
acteristics of each isolate in a clinical polymicrobial cul-
ture to better understand the nature of interactions, and
multiple organisms commonly isolated together from
Table 4 Clinical and microbiological characteristics associated with patients experiencing cure, without relapse/reinfection, or
chronic infectiona
Total cure, initial
infection (n = 101)
Relapse/reinfection, or
chronic infection (n = 30)
P-value Multivariate P-value
Median Age, years (IQR) 28 (23, 41) 30 (22, 41) 0.44
Male 91 (91 %) 24 (80 %) 0.14 NS
Military Service 75 (75 %) 17 (57 %) 0.06 NS
Combat Trauma 68 (68 %) 16 (53 %) 0.16 NS
Burn 38 (38 %) 14 (47 %) 0.37
% TBSA burn (IQR) 53.5 % (28, 60) 77 % (59, 85) <0.01 NS
Coronary Artery Disease 3 (3 %) 0 0.34
Chronic Kidney Disease 0 0
ESRD 0 0
Diabetes 6 (6 %) 5 (17 %) 0.06 NS
Median Hct on Culture Date (IQR) 24.2 (22, 30) 23.6 (22, 27) 0.53
Median WBC on Culture Date (IQR) 9.7 (7, 13) 7 (5, 12) 0.11 NS
Median ESR on Culture Date (IQR) 91.5 (65, 114) 106 (104, 114) 0.48
Median CRP on Culture Date (IQR) 18.9 (7, 21) 16.1 (9, 30) 0.14 NS
Received Appropriate Empiric Antibiotics 39 (39 %) 16 (53 %) 0.28
Median Prior Duration of Antibiotics, Days (IQR) 6 (2, 8) 4 (2, 9) 0.57
A. calcoaceticus-baumannii complex 34 (34 %) 6 (20 %) 0.41
E. coli 19 (19 %) 5 (17 %) 0.79
K. pneumoniae 25 (25 %) 7 (23 %) 0.87
P. aeruginosa 9 (9 %) 7 (23 %) 0.03 NS
S. aureus 14 (14 %) 6 (20 %) 0.41
MSSA 1 (1 %) 5 (17 %) <0.01 NS
MRSA 12 (13 %) 1 (3 %) 0.14 NS
Polymicrobial Event 41 (41 %) 7 (23 %) 0.09 NS
Blood Culture 23 (23 %) 11 (37 %) 0.13 NS
Central Line Associated 9 (39 % n = 23) 0 0.12 NS
Respiratory Culture 4 (4 %) 4 (13 %) 0.08 NS
Urine Culture 6 (6 %) 4 (13 %) 0.24
Foley Catheter Associated 2 0 0.44
Wound Culture 68 (68 %) 11 (37 %) <0.01 NS
Orthopedic Device Related 13 (19 %, n = 68) 5 (25 %, n = 11) 0.50
Median Number of Surgeries (IQR) 7 (4, 9) 3 (2, 9) 0.15 NS
aPatients who died during initial infection are excluded from this analysis
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polymicrobial wound infections could be studied together
to determine the influence of multiple species on biofilm
formation.
Ultimately, the in vitro formation of biofilms may not be
related to the in vivo phenotype, and the in vitro formation
of biofilms may underrepresent the biofilm forming cap-
ability of an organism. For example, plasma enhances the
in vitro biofilm formation of S. aureus. Current techniques
assessing in vitro biofilm formation often exclude factors
that impact expression of this phenotype in an in vivo
infection, and laboratory protocols standardizing biofilm
assessment are lacking. It is also possible that while iso-
lates may have the ability to form biofilms in vitro and in
vivo, this phenotype may not always be expressed in a par-
ticular infection. Furthermore, the link between the in
vitro phenotype and clinical outcome is still unclear, and
further studies are required to establish this link.
Conclusions
Bacterial species, but not clinical variables, were found to
be independently associated with biofilm formation in the
present study. No clinical or microbiological factors were
found to be significantly associated with relapse/reinfection,
or chronic infection on multivariate analysis. This analysis
of potential clinical risk factors and infectious outcomes of
a large data set is an important addition to the understand-
ing of this phenotype’s role in disease. Continued investiga-
tion into infectious outcomes is warranted to balance our
in vitro understanding with the in vivo implications.
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